ALNY - Alnylam U.S. label expansion for amyloidosis drug denied
2023-10-09 07:49:29 ET
More on Alnylam
- Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility
- Alnylam: Unlimited Promise Or Unlimited Losses?
- Alnylam Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Ionis, AbbVie, Alnylam draw bullish views at Raymond James
- Citi says concerns over FDA approval of Alnylam drug are "overdone"
For further details see:
Alnylam U.S. label expansion for amyloidosis drug denied